Aetna, Inc.

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 12, 2012, 10:06 AM

    Aetna (AET), which is holding its investor day, joins United Health and Cigna in providing 2013 guidance that's below consensus. Aetna forecasts EPS of at least $5.40 vs consensus of $5.52 and revenue growth of 9% to $38.6B vs $38.91B. Predicts that commercial-medical costs will rise 6.5%, the same as this year. BMO analyst Dave Shove says the outlook reflects "management’s cautious stance on guiding high." Shares +4.2%.

    | Dec. 12, 2012, 10:06 AM
  • Dec. 7, 2012, 9:34 AM

    Aetna (AET +2.4%) settles for $120M (subject to judge's approval) a class action suit relating to payments of claims to Aetna members who were served by non-contracted health-care providers. In other news, the stock is upgraded to Overweight with $52 price target by JPMorgan.

    | Dec. 7, 2012, 9:34 AM
  • Nov. 30, 2012, 12:30 PM

    More on Questcor (QCOR -6.4%): Aetna's (AET +0.3%) latest bulletin shows no change from its position first taken in September on Acthar. The insurer is still limiting reimbursement of the drug only for the treatment of infantile spasms. AET asserts that the drug's other approved uses are medically unnecessary or unproven.

    | Nov. 30, 2012, 12:30 PM | 2 Comments
  • Nov. 21, 2012, 10:40 AM

    Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news.

    | Nov. 21, 2012, 10:40 AM | 11 Comments
  • Sep. 28, 2012, 3:43 PM

    Dendreon (DNDN +3.8%) bucks a weak tape today after Aetna (AET -0.4%) indicated on its website that it would pay for additional prostate cancer patients to be treated with Provenge, saying it now considers it to be medically necessary for treatment.

    | Sep. 28, 2012, 3:43 PM
  • Sep. 21, 2012, 2:38 PM

    Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of nearly 50%, as Roth Capital joins the chorus of analysts calling the reaction to the Aetna (AET) situation "overblown." QCOR's conference call yesterday "indicated that a highly-engaged and well-prepared reimbursement practice by QCOR has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers." the firm said in a note to clients.

    | Sep. 21, 2012, 2:38 PM
  • Sep. 20, 2012, 11:38 AM

    More on Questcor (QCOR +8.4%) conference call: COO Steve Cartt says insurance reimbursement for Acthar was already complicated before Aetna's (AET) coverage limitations, but QCOR is experienced in securing coverage for appropriate patients. "We anticipate that insurance coverage for Acthar will continue to be available" for the right patients."

    | Sep. 20, 2012, 11:38 AM
  • Sep. 19, 2012, 12:35 PM

    Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.

    | Sep. 19, 2012, 12:35 PM | 4 Comments
  • Sep. 19, 2012, 10:31 AM

    Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms.

    | Sep. 19, 2012, 10:31 AM | 4 Comments
  • Aug. 20, 2012, 9:10 AM
    Premarket gainers: CVH +19%.
    Losers: ZAGG -13%. PSTI -6%. BBY -6%. LOW -5%.
    | Aug. 20, 2012, 9:10 AM | 1 Comment
  • Jul. 31, 2012, 2:04 PM

    Shares of Humana (HUM -13%) get slammed this morning, a day after the managed-care provider missed the mark on Q2 earnings and cut its profit outlook for the year. The dismal report is taking down more than one insurer that otherwise might have had an up day: Aetna (AET -1.9%), WellPoint (WLP -3.5%), UnitedHealth (UNH -3%).

    | Jul. 31, 2012, 2:04 PM | 3 Comments
  • Jul. 27, 2012, 2:26 PM

    Aetna (AET +2.7%) authorizes an additional $750M to its buyback program, in addition to the approximately $248M of repurchase authority currently available under it's existing authorization as of June 30. The company intends to continue buying shares in the open market as necessary. AET has been active over the past quarter, having had approximately $828M of repurchase authority still left available as of March 31.

    | Jul. 27, 2012, 2:26 PM
  • Jul. 25, 2012, 11:36 AM

    Health insurers take a pummeling after Wellpoint's (WLP -12%) miserable Q2 report, even though some analysts say that the company has specific challenges. Citigroup's Carl McDonald reckons management could come under pressure. Still, HealthNet (HNT) -10%, UnitedHealth (UNH) -5.6%, Coventry (CVH) -4.9%, Humana (HUM) -3%, Cigna (CI) -3.9% and Aetna (AET) -4.9%.

    | Jul. 25, 2012, 11:36 AM | 1 Comment
  • Jun. 29, 2012, 3:23 PM

    Following a brief rebound at the open today, health insurance stocks resume their downward trajectory on the back of yesterday's Supreme Court decision: UnitedHealth (UNH -2.5%), WellPoint (WLP -3.2%), Aetna (AET -3%), HealthNet (HNT -0.7%) and Coventry Health Care (CVH -2%).

    | Jun. 29, 2012, 3:23 PM | 16 Comments
  • Jun. 28, 2012, 11:09 AM

    Wells Fargo is saying to buy managed care names on the back of the Supreme Court decision. The firm notes that the decision removes a big overhang in the sector and is actually a positive over the long term. Top names it recommends buying: Aetna (AET -4%), Coventry Health (CVH -3.6%), Humana (HUM -3.2%) and UnitedHealth (UNH -3.6%).

    | Jun. 28, 2012, 11:09 AM | 1 Comment
  • Jun. 28, 2012, 10:22 AM

    Healthcare stocks that are down following the Supreme Court opinion on the Healthcare Act include: CVH -1.3%, UNH -1.1%, AET -1.2%, CI -1.5%, CHSI -0.5%, WLP -2.5%, HUM -2%. Those that are up include: UAM +0.8%, MOH +6.3%, HNT +3.1%.

    | Jun. 28, 2012, 10:22 AM | 1 Comment
Company Description
Aetna Inc. is a health care benefit company, which offers traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans.
Sector: Healthcare
Country: United States